MRC/ABPI COPD Consortium Work Package 1: COPD Phenotyping

慢性阻塞性肺病（过去被称为慢性支气管炎和肺气肿）是一种常见疾病，给患者带来相当大的困难。制药行业在将COPD的新疗法推向市场方面一直相对不成功，许多产品在首次给患者使用时就失败了。这在很大程度上是因为并非所有的慢性阻塞性肺病患者都是一样的，药物可能会治疗疾病的某些方面，因此更有可能使一些患者受益，但不是所有患者。我们建议尝试了解是什么使COPD患者彼此不同，并利用这些差异来进一步了解哪种类型的药物将使哪种类型的人受益。使用这种方法，我们的目标是识别血液和痰中的标志物，这将有助于我们预测COPD的进展和对治疗的反应。

COPD (which used to be called chronic bronchitis and emphysema) is a common disease which causes considerable difficulty to sufferers. The pharmaceutical industry has been relatively unsuccessful in bringing new treatments to the marketplace for COPD, with many products failing when they are first given to patients. This is largely because not all COPD sufferers are the same and it is likely that drugs will treat certain aspects of the disease and therefore are more likely to benefit some but not all patients. We propose to try to understand what makes people with COPD different from each other and to use these differences to further our understanding of which types of drugs will benefit which types of people. Using this approach we aim to identify markers in blood and sputum that will help us to predict the progression of COPD and response to therapy.